Prelude Capital Management’s Stoke Therapeutics STOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-7,592
Closed -$248K – 1618
2026
Q2
$248K Buy
+7,592
New +$244K 0.02% 873
2026
Q1
– Sell
-6,369
Closed -$202K – 1568
2025
Q4
$202K Buy
+6,369
New +$191K 0.01% 1059
2025
Q1
– Sell
-29,528
Closed -$326K – 1511
2024
Q4
$326K Sell
29,528
-20,372
-41% -$250K 0.02% 767
2024
Q3
$613K Buy
+49,900
New +$707K 0.04% 540

Other funds holding STOK

Prelude Capital Management's STOK Position: Q3 2026 in Review

Prelude Capital Management sold out of Stoke Therapeutics (STOK) in Q3 2026, closing a stake of 7,592 shares — an estimated $248K sold.

Prelude Capital Management first reported a position in STOK in Q3 2024 and held it in 4 quarters. The position peaked at $613K in Q3 2024. 185 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

  • Prelude Capital Management reported no remaining Stoke Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Prelude Capital Management sold 7,592 Stoke Therapeutics shares in Q3 2026, an estimated $248K.
  • Prelude Capital Management first reported a position in Stoke Therapeutics in Q3 2024 and held it in 4 quarters.
  • Prelude Capital Management's Stoke Therapeutics position peaked at $613K in Q3 2024.
  • 185 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on Prelude Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.